Blueprint Protocol

The Blueprint Protocol is bryan johnson’s closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs and biomarkers should have more authority than cravings or cultural defaults.

Design pattern

The protocol has the structure of an autonomous control system:

1. Sensors: bloodwork, imaging, sleep data, fitness tests, oral/skin/organ metrics, epigenetic clocks, and other biomarkers.
2. Objective: reduce speed of aging and optimize organ/biomarker states.
3. Policy: diet, exercise, sleep, supplements, medications, light, heat, oral care, and other interventions.
4. Feedback: repeat measurements and adjust.
5. Public ledger: publish routines/results through the web, X/Twitter, and Blueprint content.

Aviation/checklist origin narrative

In a July 28, 2026 autobiographical essay, Johnson traced this control-system style to flight training. He described aviation as a culture that assumes human fallibility and responds with preflight checks, phase-specific procedures, emergency manuals, and active risk management. He says he transferred that logic to food decisions by having “Morning Bryan” set a no-food-after-5 p.m. rule before the lower-willpower evening period, then expanded the system to food type, amount, and timing.

The essay is useful for understanding why Blueprint is presented as automation rather than daily willpower: Johnson links aviation, Kernel, AI, and the “Autonomous Self” directly to Don’t Die. It remains a personal retrospective. It does not establish that the meal cutoff caused his reported sleep, weight, fatigue, or energy changes; it is not a universal meal-timing recommendation or evidence that the system treats depression.

Current protocol stack

The public 2026 protocol emphasizes foundational habits: lower resting heart rate before bed, earlier meals, screens off before bed, consistent sleep, exercise, nutrient-dense food, oral hygiene, skin/hair routines, clean water, and measurement.

Johnson’s May 24, 2026 sleep post adds a tactical version of the same sleep discipline: when expecting to stay up past his 8pm bedtime, he said he took a nap first and argued that “front-loading” sleep is preferable to trying to repay sleep debt afterward because circadian timing still matters. This should be read as Johnson’s personal protocol advice rather than a general medical recommendation.

Johnson’s April 2026 morning routine is an example implementation: 8:30pm bedtime, ~5am wake, oral hygiene, 10,000 lux light, breath work, pre-workout nutrition/supplements, 90 minutes exercise, sauna, red/NIR light, optional shockwave therapy, shower/hair/skincare, and a breakfast of vegetables/legumes/EVOO/berries/nuts/seeds.

On June 19, 2026, a high-engagement routine post compressed that posture into a seven-day checklist: stop food four hours before sleep, screens off 60 minutes before bed, read for 10 minutes before sleep, get light in the eyes on waking, and exercise daily. It is useful as a current, low-tech summary of Johnson’s recurring sleep/wake advice; it should still be presented as his habit framing rather than personalized medical guidance.

On July 23, Johnson supplied a compact meal-timing feedback example: he reported a sleep heart rate of 42 bpm when he finished eating at noon versus 44 bpm when he finished at 2 p.m. The value for understanding Blueprint is the input/output framing—small behavioral changes become measured protocol variables—not the two readings as universal targets or proof that meal timing alone caused the difference.

Iteration and reversals

The protocol is not static. Johnson’s public posts include stopping or pausing interventions when measurements disappoint. A 2025 @bryan_johnson post says he paused metformin after five years because it appeared to build energy capacity while limiting his ability to use much of it.

Prescription-therapeutics expansion

On June 9, 2026, Johnson announced a prescription medication platform under the Blueprint/Don’t Die umbrella, naming Tadalafil/Cialis, Metformin, Oral Minoxidil, Tretinoin, Estradiol, and Acarbose as prescriptions he personally uses and says are dispensed through licensed doctors and pharmacies. This is a meaningful product expansion from routines, supplements, foods, tests, and certified products into clinician-mediated prescription access.

On June 12, he gave one concrete example: daily 5 mg Tadalafil/Cialis, which he framed as blood-flow/longevity support and not just sexual-health treatment. The public claim cites observational associations with lower mortality and cardiovascular/neurological outcomes, but Johnson’s own post caveats that association is not causation and that the information is not medical advice. The dashboard should preserve that distinction: useful evidence of where Blueprint is moving, not a treatment recommendation.

On June 22, Johnson announced a major expansion of the same prescription layer, now branded Immortals Rx, under the headline “microdose GLP-1s,” “peptides,” and “NAD+.” Newly listed items included semaglutide/Wegovy, tirzepatide/Zepbound, SGLT2 inhibitors Jardiance and Brenzavvy, additional sex/arousal/skin/hair peptide complexes, glutathione, and NAD+, alongside the existing tadalafil/metformin/minoxidil/tretinoin/acarbose stack. This is the strongest public signal so far that the Rx business is widening from a short list of Johnson’s own drugs into GLP-1, peptide, and NAD+ catalogs. It should be presented as Immortals/Blueprint commercial positioning; off-label longevity efficacy and safety are not established by the announcement.

On July 22, Johnson made the GLP-1 catalog more specific, saying Immortals Rx now lists six options: Zepbound, Wegovy injections, Wegovy tablets, Foundayo tablets, compounded tirzepatide, and compounded semaglutide. He tied the list to weight loss, “food noise,” and possible longevity relevance after an Australia time-zone shift. This is a concrete commercial update, but the post names no studies and does not independently establish formulation status, availability, prescribing criteria, compounded-treatment safety, or efficacy for longevity.

On August 3, Johnson extended the prescription narrative into cancer research by quote-posting a summary claiming that sildenafil plus statins may interfere with tumor-cell cholesterol use. He cited lower colorectal-cancer mortality and metastasis figures and proposed that the mechanism could apply to tadalafil, while explicitly saying the study was preclinical and human evidence observational. This does not announce a new product or protocol and does not establish that sildenafil, tadalafil, or statins prevent metastasis. It remains a low-confidence interpretation linked to an existing commercial prescription line, not treatment guidance.

Jet lag and routine snapshots

The June 2026 batch also included self-reported jet-lag recovery timelines and a caffeine + melatonin recovery protocol Johnson said he was testing, plus a breakfast snapshot centered on vegetables, legumes, mushrooms, herbs, seeds, and olive oil. These are examples of the measurement loop in public: an intervention or routine is narrated, tied to biomarkers or recovery, then folded back into the protocol story.

On July 22, Johnson posted another personal routine snapshot: asleep at 8 p.m., awake at 4:30 a.m., then breathwork, oral care, light and red-light exposure, protein/collagen/EVOO/berries, IHHT, work, stool/saliva/blood/urine testing, exercise, a 200°F dry sauna, and a later plant-led meal. It documents his current stack but is not evidence that the combined routine improves longevity or a template readers should follow.

On June 18, Johnson posted the outcome half of that jet-lag test after returning from Australia: 300 mg caffeine in the morning plus 3 mg melatonin before bed, which he said accelerated body-clock resynchronization and was observable “live” via blood glucose. This is useful as protocol logging and follow-up, but still N=1 self-report rather than dosing guidance or proof that the intervention caused recovery.

Microbiome product — Akkermansia + butyrate

The same June 18 source also added a commercial protocol/product signal: Blueprint launched a microbiome supplement pairing Akkermansia muciniphila with butyrate triglycerides. Johnson framed Akkermansia around age-related decline, gut-barrier integrity, glucose regulation, insulin sensitivity, and Amuc_1100/TLR2 signaling, while framing butyrate triglycerides as direct epithelial support. The dashboard should separate those mechanism claims from product-specific evidence; the launch is notable, but not independent validation of gut or metabolic benefit.

Skin / UV protection

On June 19, 2026, Johnson posted a skin-aging self-measurement from his Australia trip: he claimed one week of Australian sun increased his skin aging by about 5% via UV damage/spots despite umbrella and peak-UV protection, then added in a reply that he has reversed his skin age by roughly 9 years since starting the project. He cited a 1,472-person comparison where Australian women showed skin-aging signs 10–20 years earlier than US women, but did not provide a full citation in-tweet. For the dashboard, this is best treated as another Blueprint readout example — skin/UV risk quantified as a metric — not independent validation of the 5% or 9-year figures and not individualized skincare advice.

Sauna heat-dose / HSP27 testing

On June 16, 2026, Johnson posted a three-session dry-sauna experiment using an ingestible temperature capsule with 30-second core-temperature readings, repeated blood draws, and specialty biomarkers. His stated question was whether sauna benefit depends on elapsed time or on body-temperature dose. Johnson claims HSP27 increased only in sessions where his core temperature stayed above 102.2°F / 39°C for roughly 15 minutes, while a shorter time above that threshold did not produce the same response.

This is useful for the dashboard because it shows Blueprint’s protocol-iteration style: define a measurable mechanism, track delivered dose inside the body, compare response, then revise the practical rule. It should not be rendered as a public sauna prescription. Extreme heat exposure can be risky, and Johnson’s thread remains N=1 biomarker evidence rather than independent proof of clinical longevity benefit.

A June 17 follow-up added a heart-rate trace from the same 56-minute 200°F / 93°C session, with Johnson reporting a 128–133 bpm peak and a spike when changing ice on his face, neck, and groin. The extra datapoint is dashboard-useful mainly because it shows how Blueprint experiments now publish physiological traces alongside biomarker claims; it does not change the N=1 status or safety caveats.

On July 23, Johnson broadened that experiment into public protocol guidance: 4–7 dry-sauna sessions per week; example thresholds of 11 minutes at 176°F / 80°C and 20 minutes at 195°F / 90.5°C; a personal path to 102.2°F / 39°C core temperature; and cautions or claims spanning acclimation, hydration/electrolytes, fertility, cold plunging, recovery, microplastics, air quality, sauna materials, clothing, and heat tolerance. The expansion is editorially important because it crosses from documenting one measured experiment into telling an audience what to do. Every item therefore remains explicitly attributed to Johnson; the post does not independently validate the dry-versus-wet/infrared distinction, the benefit thresholds, the fertility or microplastics claims, or a reader-safe universal protocol.

N-of-1 methodology essay (June 2026)

The same daily batch included Johnson’s most formal public defense of Blueprint’s method to date, prompted by a Nature feature. With the Blueprint & Immortals Medical and Science Team, he argued that RCTs remain the gold standard for population average effects and safety, but are structurally limited for tuning individualized intervention combinations over time. For the public KB, this is best treated as a methodology update: it clarifies why Blueprint keeps emphasizing dense personal measurement, while also making the evidence boundary explicit because the essay’s examples are still observations needing validation.

Critical context: changes are hard to interpret because dozens of variables move at once. In conventional evidence hierarchy, this is hypothesis-generating self-experimentation, not proof of general efficacy.

Disease-resolution and eye-health agenda

On July 20, 2026, Johnson said an unspecified incurable-disease diagnosis had shifted his project from “longevity staples” toward disease resolution and frontier biotech. In a separate eye-health thread that day, he distinguished general diet and supplement discussion from what he wants to see: robust measurement, diagnosis of dysfunction, and protocols intended to correct it. Together the posts suggest a change in emphasis—from broad longevity routines toward disease- and organ-specific engineering—but they do not identify the disease, measurement set, dysfunction, intervention, or outcome. The dashboard records a strategic agenda, not a demonstrated protocol, cure, or reader medical guidance.

On July 21, the eye-health agenda gained a concrete measurement but still no public protocol: Johnson reported collecting tears with paper strips for a $1,800 specialty-lab panel across 15 inflammatory, tissue-degradation, and regenerative-signaling biomarkers. He said the readings would establish the ocular-surface environment and track progress, with an eye protocol forthcoming. No result, diagnosis, intervention, reference range, clinical-utility evidence, or outcome was published, so the dashboard records an N=1 measurement plan rather than eye-health guidance.

On August 18, the agenda landed a diagnosis and a disclosed intervention stack. After visiting an eye doctor for a stye, Johnson said infrared meibography and Schirmer testing showed advanced meibomian-gland dysfunction with meaningful gland dropout plus concurrent aqueous deficiency. He published a four-therapy in-office stack—intense pulsed light, radiofrequency, intraductal probing (the Maskin protocol), and 630nm low-level red light—alongside home compresses, preservative-free and lipid-replacement drops, and tear-stimulation devices, and reported a self-measured 30% improvement in gland function on imaging. He also named systemic drivers that sit inside his own longevity protocol: a topical anti-androgen used for hair growth, low insulin/IGF-1 signaling, and a prior subclinical thyroid flare. The post itself concedes the probing science is unsettled and that four simultaneous therapies cannot be attributed individually. The dashboard records an attributed N=1 diagnosis-and-intervention account—not a validated eye-care protocol, evidence the therapies work in general, or medical advice.

Immortals disease infrastructure and female-health baseline

On July 24, Johnson described Immortals’ disease-resolution pivot as a company buildout. Alongside the existing nutrition, prescription, hormone, peptide, biomarker, and concierge layers, he named induced pluripotent stem cells, organoids, deep cellular characterization, and personalized therapy development as new directions intended to help individuals investigate and resolve their own health issues. This extends Blueprint’s measure–intervene–retest loop toward personalized biotech R&D, but the post does not establish an operational clinical platform, diagnostic accuracy, treatment safety, or any cure or outcome.

On July 25, Johnson published a more operational version of Kate Tolo’s baseline: 100 days before interventions, 14 million claimed menstrual-cycle data points, 100+ tasks a day, 50+ devices, and a 12-person medical team. The schedule combines repeated biological samples, hormone and metabolic measures, functional and sensory tests, imaging, wearables, microbiome work, exercise, sleep, mood, and routine care. Its dashboard value is visibility into protocol operations and burden; it remains a single N=1 program with no published results, validated general female-health protocol, or reader guidance.

On August 4, Johnson compared the build process directly: he said his own longevity infrastructure took five years to assemble, including the doctors, protocols, measurements, and mistakes, while his team built Tolo’s protocol in 90 days and made it “better.” The notable signal is operational rather than clinical—Blueprint is being presented as infrastructure a team can reproduce and improve, not only as Johnson’s personal N=1 routine. The source does not define “better,” publish comparative measurements, or report outcomes, so it is not evidence that Tolo’s protocol is clinically superior, generalizable, or appropriate for readers.

August measurement-scale and research-watch updates

On August 12, Johnson reported a 47-tube, 250 mL blood draw for single-cell sequencing of circulating immune cells and a broad panel spanning inflammation, oxidative stress, vascular health, metabolic and lipid regulation, glucose regulation, and brain-related signals. On August 13, he promoted a Baseten event organized around biological-age evaluations for brain, skin, strength, balance, reaction speed, and mobility. Together the posts show Blueprint’s continued emphasis on molecular depth plus functional breadth, but neither publishes results, test-validity evidence, a diagnosis, or a protocol change readers should copy.

Johnson also summarized an unnamed mouse study in which an intranasal gene therapy reportedly restored age-reduced downstream brain-fluid flow. This is relevant to his longevity-research narrative, not evidence that Blueprint uses the intervention or that a human therapy is available. The post supplies no paper, human data, translational safety evidence, or clinical outcome.

Automation analogy

Johnson explicitly connects Blueprint to automation: in a 2024 X post he wrote that the era is defined by automation in software engineering, self-driving, and health/wellness, and that Blueprint is automation toward peak health and age escape velocity.

This makes Blueprint relevant to the wiki’s AI-agent themes: it is essentially an agentic/self-driving loop over the body, with measurements as context, protocols as tools, and biological age as reward signal.

Evidence tiers

Related pages

• blueprint
• bryan johnson
• dont die
• algorithmic health — the broader measurement-and-policy pattern behind the protocol.